FTSE live: market report - as it happened July 14, 2011 - Telegraph.co.uk
Fri, 15 Jul 2011 05:41Analysts described Shire as “one of the best positioned European pharmaceutical companies”, saying their revenue estimates were 4pc to 8pc ahead of company-compiled consensus, while their earnings-per-share estimates are 6pc to 7pc ahead. ...
MARKET REPORT: Shire soars on dose of bid talk - This is Money
Mon, 11 Jul 2011 21:08AstraZeneca, which has often been mentioned in the same breath as Shire, fell 15.5p to 3113.5p. Dealers reached for the valium as share prices on both sides of the pond continued to move lower. Friday's acutely disappointing US jobs data for June ...
Market Report: Yule Catto retreats as takeover hopes fade - The Independent
Tue, 12 Jul 2011 23:04Bid rumours may have been a large part of the winning formula that has sent its share price soaring over the past few months, but Yule Catto's takeover hopes were dealt a blow yesterday, prompting the speciality chemicals company to sink ...
What Does It Take to Swing the IPO Window Open for Biotechs? - Genetic Engineering News
Wed, 22 Jun 2011 04:18Tranzyme Pharma, which focuses on small molecule treatments for gastrointestinal motility disorders, climbed from its $4 share price during its $48 million IPO to $4.51 per share. The company initially sought $12 a share when it filed in November. ...
Cheap and expensive investment trusts - Investors Chronicle
Tue, 05 Jul 2011 10:26The fund's six-month average price typically lies between a 2 per cent premium and a 9 per cent premium. The research echoes earlier figures from the AIC and Morningstar, showing that investment companies with an income-orientated focus are trading at ...
Sector:
Which 3 Stocks Would Warren Buffett Buy?
